Reparixin, an antagonist of CXCR1/2, in experimental laminitis
Section snippets
Take-home message
Although reparixin did not interfere with the development of clinical signs, it prevented laminar inflammation and epidermal deterioration in the treated group.
Materials and Methods
Twelve light horses (305 ± 35 kg) were given OF (10 g/kg PO) and divided into 2 groups: treated (reparixin, 30 mg/kg IV at 6, 12, 18, and 24 h after OF) and untreated. Clinical and hematologic variables were recorded before and 6, 12, 18, 24, 36, 48, 60, and 72 h after OF administration. Laminar biopsy samples were taken before and 12, 36, and 72 h after OF. Histological sections were stained with PAS and scored from 0 to 6 for epidermal cell and basal membrane changes. The RNA expression of
Results
Laminitis signs were mild in both groups. Reparixin treatment did not affect clinical signs or cause any apparent adverse effect. Increases from basal levels in PAS grades and in IL-1β and IL-6 RNA expressions were seen in untreated but not in treated horses.
Discussion and Conclusions
Although the reparixin therapy protocol did not interfere with the development of clinical signs, it prevented laminar inflammation and epidermal deterioration in the treated group. Reparixin shows potential therapeutic effects for acute laminitis.